Scil Proteins, a private biotech company specialized in the research, development and production of recombinant proteins, announced today that it has signed a supply agreement with Actavis, one of the world's leading generic pharmaceutical companies, for the future manufacturing of Reteplase. Financial terms were not disclosed.
Reteplase is a recombinant protein and the active ingredient in the medicinal product Rapilysin® for thrombolytic treatment of myocardial infarction. Scil Proteins originally signed an agreement with Roche in June 2008 for process transfer and manufacture of Reteplase. The protein was the first biologic which was invented, developed and produced in Germany. It has a demanding production process requiring considerable experience in protein refolding that only Scil Proteins could deliver. Actavis owns rights on the Reteplase production process and on Rapilysin® for European and worldwide distribution excluding USA and Canada.
"We are extremely happy to be working for one of the world's leading players in first-class generic pharmaceuticals" commented Dr. Ulrike Fiedler, CEO of Scil Proteins. "This product has a complex production process but one that we have considerable experience in."
As well as the previous agreement with Roche, this new agreement with Actavis adds to Scil Proteins' portfolio of contract development and manufacturing clients. Previous customers have included global pharma companies such as Pfizer, Novartis, Sanofi, Lundbeck, large biotech companies such as Austria-based Intercell as well as numerous small biotech companies.
Maternal medications linked to changes in protein and fat levels in human milk